Mildronate: Cardioprotective action through carnitine-lowering effect

Trends in Cardiovascular Medicine

Volumn 12, Issue 6, 2002, Pages 275-279

  Dambrova, Maija ^a   Liepinsh, Edgars ^a   Kalvinsh, Ivars ^a  

^a LATVIAN INSTITUTE OF ORGANIC SYNTHESIS   (Latvia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CARBOHYDRATE; CARNITINE; FATTY ACID; GLUCOSE; MILDRONATE; RANOLAZINE; TRIMETAZIDINE;

CARBOHYDRATE METABOLISM; CELL METABOLISM; DRUG EFFECT; DRUG MECHANISM; ENERGY METABOLISM; FATTY ACID OXIDATION; GLUCOSE OXIDATION; HEART FUNCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART PROTECTION; HEART STRESS; HUMAN; HYPOTHESIS; MEMBRANE STRUCTURE; PRIORITY JOURNAL; REVIEW; TISSUE LEVEL;

EID: 0036701588     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1050-1738(02)00175-5     Document Type: Review

References (36)

1. Asaka N., Muranaka Y., Kirimoto T., Miyake H. Cardioprotective profile of MET-88, an inhibitor of carnitine synthesis, and insulin during hypoxia in isolated perfused rat hearts. Fundam Clin Pharmacol. 12:1998;158-163.
2. Bieber L.L. Carnitine. Annu Rev Biochem. 57:1988;261-283.
3. Boicov SA, Ovchinikov JB, Zaharova AI, Buliko TM: 1998. Use of mildronate in the treatment of heart failure-I in 40-50 year old men [in Russian]. Klin Med Patofiz 1-2:25-29.
4. Bremer J. Carnitine-metabolism and functions. Physiol Rev. 63:1983;1420-1480.
5. Depre C., Taegtmeyer H. Metabolic aspects of programmed cell survival and cell death in the heart. Cardiovasc Res. 45:2000;538-548.
6. Dhar P.K., Grupp I.L., Schwartz A.et al. Reduction of carnitine content by inhibition of its biosynthesis results in protection of isolated guinea pig hearts against hypoxic damage. J Cardiovasc Pharmacol Ther. 1:1996;235-242.
7. Eremeev A, Kalvinsh I, Semenikhina V, et al. inventors: 1984, 1984-11-06. 3-(2,2,2-Trimethylhydrazinium) propionate and method for the preparation and use thereof. US patent 4481218.
8. Frantsuzova S.B., Jatsenko V.P., Zotov A.S.et al. Pharmacodynamics of mildronate. a review J Ukraine Acad Med Sci. 3:1997;612-624. [in Russian].
9. Georges B., Le Borgne F., Galland S.et al. Carnitine transport into muscular cells. Inhibition of transport and cell growth by mildronate. Biochem Pharmacol. 59:2000;1357-1363.
10. 2+ uptake activity in rats with congestive heart failure following myocardial infarction. Mol Cell Biochem. 209:2000;39-46. a.
11. Hayashi Y., Kirimoto T., Asaka N.et al. Beneficial effects of MET-88, a gamma-butyrobetaine hydroxylase inhibitor in rats with heart failure following myocardial infarction. Eur J Pharmacol. 395:2000;217-224. b.
12. Hayashi Y., Muranaka Y., Kirimoto T.et al. Effects of MET-88, a gamma-butyrobetaine hydroxylase inhibitor, on tissue carnitine and lipid levels in rats. Biol Pharm Bull. 23:2000;770-773. c.
13. Heidemanis K., Balcere I., Kalvinsh I. Mildronate-plasma membrane interaction mechanisms. Proc Latv Acad Sci. 11:1990;108-115.
14. Jackson G. Combination therapy in angina. a review of combined haemodynamic treatment and the role for combined haemodynamic and cardiac metabolic agents Int J Clin Pract. 55:2001;256-261.
15. Karpov R.S., Koshelskaja O.A., Vrublevskij A.V.et al. Clinical efficacy and safety of mildronate in patients with ischemic heart disease and chronic heart failure. Kardiologija. 6:2000;69-74. [in Russian].
16. 2+-uptake stimulator for treating chronic heart failure Cardiovasc Drug Rev. 17:1999;75-86.
17. Kirimoto T., Nobori K., Asaka N.et al. Beneficial effect of MET-88, a gamma-butyrobetaine hydroxylase inhibitor, on energy metabolism in ischemic dog hearts. Arch Int Pharmacodyn Ther. 331:1996;163-178.
18. Kuwajima M., Harashima H., Hayashi M.et al. Pharmacokinetic analysis of the cardioprotective effect of 3-(2,2, 2-trimethylhydrazinium) propionate in mice. inhibition of carnitine transport in kidney J Pharmacol Exp Ther. 289:1999;93-102.
19. Lango R., Smolenski R.T., Narkiewicz M.et al. Influence of L-carnitine and its derivatives on myocardial metabolism and function in ischemic heart disease and during cardiopulmonary bypass. Cardiovasc Res. 51:2001;21-29.
20. Lopaschuk G.D. Optimizing cardiac energy metabolism. how can fatty acid and carbohydrate metabolism be manipulated? Coron Artery Dis. 12(Suppl 1):2001;S8-S11.
21. Marin J., Marin E., Gutierrez-Iniguez M.A.et al. Mechanisms involved in the hemodynamic alterations in congestive heart failure as a basis for a rational pharmacological treatment. Pharmacol Ther. 88:2000;15-31.
22. Morin D., Hauet T., Spedding M., Tillement J. Mitochondria as target for antiischemic drugs. Adv Drug Deliv Rev. 49:2001;151-174.
23. Napoli C., Pinto A., Cirino G. Pharmacological modulation, preclinical studies, and new clinical features of myocardial ischemic preconditioning. Pharmacol Ther. 88:2000;311-331.
24. Nedoshivin A.O., Petrova N.N., Kutuzova A.E., Perepech N.B. Effect of mildronate on life quality of patients with chronic heart failure. Ter Arkh. 71:1999;10-12. [in Russian].
25. Ramsay R.R., Gandour R.D., van der Leij F.R. Molecular enzymology of carnitine transfer and transport. Biochim Biophys Acta. 1546:2001;21-43.
26. Schofield R.S., Hill J.A. Role of metabolically active drugs in the management of ischemic heart disease. Am J Cardiovasc Drugs. 1:2001;23-35.
27. Schulz R., Cohen M.V., Behrends M.et al. Signal transduction of ischemic preconditioning. Cardiovasc Res. 52:2001;181-198.
28. Semigolovskii N. Use of antihypoxants in the acute period of myocardial infarction. Anesteziol Reanimatol. 2:1998;56-59. [in Russian].
29. Simkhovich B.Z., Shutenko Z.V., Meirena D.V.et al. 3-(2,2,2-trimethylhydrazinium) propionate (THP). a novel gamma-butyrobetaine hydroxylase inhibitor with cardioprotective properties Biochem Pharmacol. 37:1988;195-202.
30. Skarda I., Klincare D., Vitols A.et al. Effect of mildronate on heart functioning, physical activity and life quality in patients of chronic heart failure. Latv Doc. 12:1995;17-24.
31. Spaniol M., Brooks H., Auer L.et al. Development and characterization of an animal model of carnitine deficiency. Eur J Biochem. 268:2001;1876-1887.
32. Stebleva T.F., Voitovich A.V., Mamaeva E.G.et al. Mechanisms of the optimization of oxygen metabolism under the effects of mafusol and mildronate during emergency implantation of hip prosthesis. Vestn Khir Im I I Grek. 159:2000;57-60. [in Russian].
33. Taegtmeyer H., King L.M., Jones B.E. Energy substrate metabolism, myocardial ischemia, and targets for pharmacotherapy. Am J Cardiol. 82:1998;54K-60K.
34. Tsoko M., Beauseigneur F., Gresti J.et al. Enhancement of activities relative to fatty acid oxidation in the liver of rats depleted of L-carnitine by D-carnitine and a gamma-butyrobetaine hydroxylase inhibitor. Biochem Pharmacol. 49:1995;1403-1410.
35. 2+-ATPase and hexokinase type I in rat hearts with myocardial infarction. Basic Res Cardiol. 95:2000;343-348.
36. Yoshisue K., Yamamoto Y., Yoshida K.et al. Pharmacokinetics and biological fate of 3-(2,2, 2-trimethylhydrazinium) propionate dihydrate (MET-88), a novel cardioprotective agent, in rats. Drug Metab Dispos. 28:2000;687-694.